Severity and management strategies of rivaroxaban-related bleeding complications in the as-treated population
| 1082 bleeding events in 762 patients . | Conservative (no treatment/compression/tamponade/transfusion) . | Surgery or intervention . | RBC . | Vitamin K . | FFP . | PCC . | rFVII . |
|---|---|---|---|---|---|---|---|
| Minor 637/1082 (58.9%) | 637/637 (100.0) | 0 | 0 | 0 | 0 | 0 | 0 |
| NMCR 379/1082 (35.0%) | 328/379 (86.5) | 51/379 (13.5) | 0 | 0 | 0 | 0 | 0 |
| Major 66/1082 (6.1%) | 41/66 (62.1) | 25/66 (37.9) | 40/66 (60.6) | 1/66 (1.5) | 6/66 (9.1) | 6/66 (9.1) | 0 |
| Total | 1006/1082 (93.0) | 76/1082 (7.0) | 40/1082 (3.7) | 1/1082 (0.1) | 6/1082 (0.6) | 6/1082 (0.6) | 0 |
| 1082 bleeding events in 762 patients . | Conservative (no treatment/compression/tamponade/transfusion) . | Surgery or intervention . | RBC . | Vitamin K . | FFP . | PCC . | rFVII . |
|---|---|---|---|---|---|---|---|
| Minor 637/1082 (58.9%) | 637/637 (100.0) | 0 | 0 | 0 | 0 | 0 | 0 |
| NMCR 379/1082 (35.0%) | 328/379 (86.5) | 51/379 (13.5) | 0 | 0 | 0 | 0 | 0 |
| Major 66/1082 (6.1%) | 41/66 (62.1) | 25/66 (37.9) | 40/66 (60.6) | 1/66 (1.5) | 6/66 (9.1) | 6/66 (9.1) | 0 |
| Total | 1006/1082 (93.0) | 76/1082 (7.0) | 40/1082 (3.7) | 1/1082 (0.1) | 6/1082 (0.6) | 6/1082 (0.6) | 0 |
rFVII, recombinant factor VII; vitamin K, vitamin K supplementation.